2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A New Pathway Promotes Adaptation of Human Glioblastoma Cells to Glucose Starvation

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Adaptation of glioblastoma to caloric restriction induces compensatory changes in tumor metabolism that are incompletely known. Here we show that in human glioblastoma cells maintained in exhausted medium, SHC adaptor protein 3 (SHC3) increases due to down-regulation of SHC3 protein degradation. This effect is reversed by glucose addition and is not present in normal astrocytes. Increased SHC3 levels are associated to increased glucose uptake mediated by changes in membrane trafficking of glucose transporters of the solute carrier 2A superfamily (GLUT/SLC2A). We found that the effects on vesicle trafficking are mediated by SHC3 interactions with adaptor protein complex 1 and 2 (AP), BMP-2-inducible protein kinase and a fraction of poly ADP-ribose polymerase 1 (PARP1) associated to vesicles containing GLUT/SLC2As. In glioblastoma cells, PARP1 inhibitor veliparib mimics glucose starvation in enhancing glucose uptake. Furthermore, cytosol extracted from glioblastoma cells inhibits PARP1 enzymatic activity in vitro while immunodepletion of SHC3 from the cytosol significantly relieves this inhibition. The identification of a new pathway controlling glucose uptake in high grade gliomas represents an opportunity for repositioning existing drugs and designing new ones.

          Related collections

          Most cited references68

          • Record: found
          • Abstract: found
          • Article: not found

          Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation.

          The energy requirements of the brain are very high, and tight regulatory mechanisms operate to ensure adequate spatial and temporal delivery of energy substrates in register with neuronal activity. Astrocytes-a type of glial cell-have emerged as active players in brain energy delivery, production, utilization, and storage. Our understanding of neuroenergetics is rapidly evolving from a "neurocentric" view to a more integrated picture involving an intense cooperativity between astrocytes and neurons. This review focuses on the cellular aspects of brain energy metabolism, with a particular emphasis on the metabolic interactions between neurons and astrocytes. Copyright © 2011 Elsevier Inc. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3.

            Tumor heterogeneity of high-grade glioma (HGG) is recognized by four clinically relevant subtypes based on core gene signatures. However, molecular signaling in glioma stem cells (GSCs) in individual HGG subtypes is poorly characterized. Here we identified and characterized two mutually exclusive GSC subtypes with distinct dysregulated signaling pathways. Analysis of mRNA profiles distinguished proneural (PN) from mesenchymal (Mes) GSCs and revealed a pronounced correlation with the corresponding PN or Mes HGGs. Mes GSCs displayed more aggressive phenotypes in vitro and as intracranial xenografts in mice. Further, Mes GSCs were markedly resistant to radiation compared with PN GSCs. The glycolytic pathway, comprising aldehyde dehydrogenase (ALDH) family genes and in particular ALDH1A3, were enriched in Mes GSCs. Glycolytic activity and ALDH activity were significantly elevated in Mes GSCs but not in PN GSCs. Expression of ALDH1A3 was also increased in clinical HGG compared with low-grade glioma or normal brain tissue. Moreover, inhibition of ALDH1A3 attenuated the growth of Mes but not PN GSCs. Last, radiation treatment of PN GSCs up-regulated Mes-associated markers and down-regulated PN-associated markers, whereas inhibition of ALDH1A3 attenuated an irradiation-induced gain of Mes identity in PN GSCs. Taken together, our data suggest that two subtypes of GSCs, harboring distinct metabolic signaling pathways, represent intertumoral glioma heterogeneity and highlight previously unidentified roles of ALDH1A3-associated signaling that promotes aberrant proliferation of Mes HGGs and GSCs. Inhibition of ALDH1A3-mediated pathways therefore might provide a promising therapeutic approach for a subset of HGGs with the Mes signature.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc.

              Aerobic glycolysis (the Warburg effect) is a core hallmark of cancer, but the molecular mechanisms underlying it remain unclear. Here, we identify an unexpected central role for mTORC2 in cancer metabolic reprogramming where it controls glycolytic metabolism by ultimately regulating the cellular level of c-Myc. We show that mTORC2 promotes inactivating phosphorylation of class IIa histone deacetylases, which leads to the acetylation of FoxO1 and FoxO3, and this in turn releases c-Myc from a suppressive miR-34c-dependent network. These central features of activated mTORC2 signaling, acetylated FoxO, and c-Myc levels are highly intercorrelated in clinical samples and with shorter survival of GBM patients. These results identify a specific, Akt-independent role for mTORC2 in regulating glycolytic metabolism in cancer. Copyright © 2013 Elsevier Inc. All rights reserved.
                Bookmark

                Author and article information

                Journal
                Cells
                Cells
                cells
                Cells
                MDPI
                2073-4409
                18 May 2020
                May 2020
                : 9
                : 5
                : 1249
                Affiliations
                [1 ]Neurosurgery, Dipartimento di Scienze Clinico-Chirurgiche e Pediatriche, Università degli Studi di Pavia, Fondazione IRCCS Policlinico S. Matteo, 27100 Pavia, Italy; azzalin.alberto@ 123456gmail.com
                [2 ]Dipartimento di Biologia e Biotecnologie, University of Pavia, 27100 Pavia, Italy
                [3 ]Proteomics and Metabolomics Institute for Biomedical Technologies (ITB-CNR), Segrate, 20090 Milan, Italy; francesca.brambilla@ 123456itb.cnr.it (F.B.); pierluigi.mauri@ 123456itb.cnr.it (P.M.)
                [4 ]Molecular Genetic Laboratory-Transplant Research Area, Fondazione IRCCS Policlinico S. Matteo, 27100 Pavia, Italy; E.Arbustini@ 123456smatteo.pv.it
                [5 ]Cryolab, University of Rome Tor Vergata, 00133 Rome, Italy; katia.basello@ 123456gek-group.com (K.B.); attilio.speciani@ 123456gek-group.com (A.S.)
                [6 ]Inflammation Society, 18 Woodlands Park, Bexley, Kent DA52EL, UK
                [7 ]Département des Neurosciences Fondamentales, Université de Lausanne, 1005 Lausanne, Switzerland; paola.bezzi@ 123456unil.ch
                [8 ]Istituto di Genetica Molecolare-CNR, 27100 Pavia, Italy
                Author notes
                [* ]Correspondence: lorenzo.magrassi@ 123456unipv.it ; Tel.: +39-338-335-5233
                Author information
                https://orcid.org/0000-0001-6037-853X
                https://orcid.org/0000-0003-2948-7994
                https://orcid.org/0000-0003-2192-5267
                https://orcid.org/0000-0002-3712-9428
                https://orcid.org/0000-0003-4364-0393
                https://orcid.org/0000-0002-8279-3600
                https://orcid.org/0000-0002-8308-2720
                Article
                cells-09-01249
                10.3390/cells9051249
                7290719
                32443613
                19134b8a-173c-482d-bb5e-14a4efa3baf0
                © 2020 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 25 March 2020
                : 15 May 2020
                Categories
                Article

                glioblastoma cells,aerobic glycolysis,glut/slc2a,shc3,parp1
                glioblastoma cells, aerobic glycolysis, glut/slc2a, shc3, parp1

                Comments

                Comment on this article